These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

440 related items for PubMed ID: 10901448

  • 21. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B, Asopa R, Basu S.
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [Abstract] [Full Text] [Related]

  • 22. Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide.
    Meisetschläger G, Poethko T, Stahl A, Wolf I, Scheidhauer K, Schottelius M, Herz M, Wester HJ, Schwaiger M.
    J Nucl Med; 2006 Apr; 47(4):566-73. PubMed ID: 16595488
    [Abstract] [Full Text] [Related]

  • 23. Technetium-99m somatostatin analogues: effect of labelling methods and peptide sequence.
    Decristoforo C, Mather SJ.
    Eur J Nucl Med; 1999 Aug; 26(8):869-76. PubMed ID: 10436200
    [Abstract] [Full Text] [Related]

  • 24. New trends in peptide receptor radioligands.
    Virgolini I, Traub T, Novotny C, Leimer M, Füger B, Li SR, Patri P, Pangerl T, Angelberger P, Raderer M, Andreae F, Kurtaran A, Dudczak R.
    Q J Nucl Med; 2001 Jun; 45(2):153-9. PubMed ID: 11476164
    [Abstract] [Full Text] [Related]

  • 25. 99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors.
    Trogrlic M, Tezak S.
    Nucl Med Rev Cent East Eur; 2016 Jun; 19(2):74-80. PubMed ID: 27479884
    [Abstract] [Full Text] [Related]

  • 26. Preclinical evaluation of [99mTc/EDDA/tricine/HYNIC0, 1-Nal3, Thr8]-octreotide as a new analogue in the detection of somatostatin-receptor-positive tumors.
    Gandomkar M, Najafi R, Shafiei M, Mazidi M, Ebrahimi SE.
    Nucl Med Biol; 2007 Aug; 34(6):651-7. PubMed ID: 17707805
    [Abstract] [Full Text] [Related]

  • 27. In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats.
    Bakker WH, Krenning EP, Reubi JC, Breeman WA, Setyono-Han B, de Jong M, Kooij PP, Bruns C, van Hagen PM, Marbach P.
    Life Sci; 1991 Aug; 49(22):1593-601. PubMed ID: 1658516
    [Abstract] [Full Text] [Related]

  • 28. Somatostatin receptor imaging in intracranial tumours.
    Schmidt M, Scheidhauer K, Luyken C, Voth E, Hildebrandt G, Klug N, Schicha H.
    Eur J Nucl Med; 1998 Jul; 25(7):675-86. PubMed ID: 9662588
    [Abstract] [Full Text] [Related]

  • 29. [Preliminary clinical application of 99Tcm-HYNIC-TOC imaging in somatostatin receptor-positive tumors].
    Li F, Chen LB, Jing HL, Du YR, Chen F.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Oct; 25(5):563-6. PubMed ID: 14650159
    [Abstract] [Full Text] [Related]

  • 30. [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation.
    Bakker WH, Albert R, Bruns C, Breeman WA, Hofland LJ, Marbach P, Pless J, Pralet D, Stolz B, Koper JW.
    Life Sci; 1991 Oct; 49(22):1583-91. PubMed ID: 1658515
    [Abstract] [Full Text] [Related]

  • 31. 99mTc-N4-[Tyr3]Octreotate Versus 99mTc-EDDA/HYNIC-[Tyr3]Octreotide: an intrapatient comparison of two novel Technetium-99m labeled tracers for somatostatin receptor scintigraphy.
    Gabriel M, Decristoforo C, Maina T, Nock B, vonGuggenberg E, Cordopatis P, Moncayo R.
    Cancer Biother Radiopharm; 2004 Feb; 19(1):73-9. PubMed ID: 15068614
    [Abstract] [Full Text] [Related]

  • 32. Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phe1-octreotide.
    Wangberg B, Forssell-Aronsson E, Tisell LE, Nilsson O, Fjalling M, Ahlman H.
    Br J Cancer; 1996 Mar; 73(6):770-5. PubMed ID: 8611378
    [Abstract] [Full Text] [Related]

  • 33. Improved kit formulation for preparation of (99m)Tc-HYNIC-TOC: results of preliminary clinical evaluation in imaging patients with neuroendocrine tumors.
    Korde A, Mallia M, Shinto A, Sarma HD, Samuel G, Banerjee S.
    Cancer Biother Radiopharm; 2014 Nov; 29(9):387-94. PubMed ID: 25379612
    [Abstract] [Full Text] [Related]

  • 34. The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment.
    Shi W, Buchanan KD, Johnston CF, Larkin C, Ong YL, Ferguson R, Laird J.
    Clin Endocrinol (Oxf); 1998 Mar; 48(3):303-9. PubMed ID: 9578820
    [Abstract] [Full Text] [Related]

  • 35. Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model.
    Schmitt A, Bernhardt P, Nilsson O, Ahlman H, Kölby L, Forssell-Aronsson E.
    Cancer Biother Radiopharm; 2005 Apr; 20(2):231-6. PubMed ID: 15869461
    [Abstract] [Full Text] [Related]

  • 36. Initial direct comparison of 99mTc-TOC and 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs.
    Cwikla JB, Mikolajczak R, Pawlak D, Buscombe JR, Nasierowska-Guttmejer A, Bator A, Maecke HR, Walecki J.
    J Nucl Med; 2008 Jul; 49(7):1060-5. PubMed ID: 18552141
    [Abstract] [Full Text] [Related]

  • 37. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.
    Capello A, Krenning E, Bernard B, Reubi JC, Breeman W, de Jong M.
    Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1288-95. PubMed ID: 16021448
    [Abstract] [Full Text] [Related]

  • 38. Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET.
    Rodrigues M, Traub-Weidinger T, Leimer M, Li S, Andreae F, Angelberger P, Dudczak R, Virgolini I.
    Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1144-51. PubMed ID: 15909194
    [Abstract] [Full Text] [Related]

  • 39. [99mTc-OCTREOTIDE in patients with neuroendocrine tumors from the GI tract].
    Gómez M, Ferrando R, Vilar J, Hitateguy R, López B, Moreira E, Kapitán M, De Lima F, Agüero B, Gabriela Villegas M, Urdaneta N, Gutiérrez E, Battegazzore A, Bayardo K, Silveira A, Lago G, Páez A.
    Acta Gastroenterol Latinoam; 2010 Dec; 40(4):332-8. PubMed ID: 21381408
    [Abstract] [Full Text] [Related]

  • 40. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors.
    Janson ET, Westlin JE, Ohrvall U, Oberg K, Lukinius A.
    J Nucl Med; 2000 Sep; 41(9):1514-8. PubMed ID: 10994731
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.